Zelira Therapeutics Limited (ZLD.AX)
| Previous close | 0.0460 |
| Open | 0.0460 |
| Bid | 0.0440 x 14831600 |
| Ask | 0.0450 x 5161300 |
| Day's range | 0.0440 - 0.0460 |
| 52-week range | 0.0430 - 0.1400 |
| Volume | 298,793 |
| Avg. volume | 1,270,095 |
| Market cap | 52.374M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0080 |
| Earnings date | 26 Aug 2021 - 30 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
We Think Zelira Therapeutics (ASX:ZLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation
Richard Hopkins has been the CEO of Zelira Therapeutics Limited ( ASX:ZLD ) since 2018, and this article will examine...
- PR Newswire
Zelira Therapeutics Expands HOPE™ Distribution in the US Through Licensing Agreement with Alternative Solutions in Washington DC
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.
